EMA/540506/2018

European Medicines Agency decision

P/0319/2018

of 12 September 2018

on the agreement of a paediatric investigation plan and on the granting of a waiver for recombinant human acid ceramidase (RVT-801) (EMEA-002266-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

An agency of the European Un on

European Medicines Agency decision

P/0319/2018

of 12 September 2018

on the agreement of a paediatric investigation plan and on the granting of a waiver for recombinant human acid ceramidase (RVT-801) (EMEA-002266-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Enzyvant Farber Ireland Ltd on 27 November 2017 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 July 2018, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant human acid ceramidase (RVT-801), solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for recombinant human acid ceramidase (RVT-801) solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Enzyvant Farber Ireland Ltd, 6th Floor South Bank House, Barrow Street, 4 – Dublin, Ireland.

EMA/PDCO/367673/2018 Corr
London, 27 July 2018

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMEA-002266-PIP01-17

Scope of the application

Active substance(s):

Recombinant human acid ceramidase (RVT-801)

Condition(s):

Farber disease

Pharmaceutical form(s):

Solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Enzyvant Farber Ireland Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Enzyvant Farber Ireland Ltd submitted for agreement to the European Medicines Agency on 27 November 2017 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 3 January 2018.

Supplementary information was provided by the applicant on 7 May 2018. The applicant proposed modifications to the paediatric investigation plan and requested a waiver.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Farber disease.

The waiver applies to:

- the paediatric population from birth to less than 3 months of age;
- solution for infusion, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of Farber disease.

2.1.1. Indication(s) targeted by the PIP

Treatment of Farber disease.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for infusion.

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	3	**Study 1** Intravenous injection tolerability and dose range-finding toxicity study of RVT-801 in juvenile rats (RVT-801-9011). **Study 2** A 13-Week Toxicity Study of RVT-801 by Intravenous Administration in Juvenile Rats Followed by a 4-Week Off-Dose Period (RVT-801-9012).

Area	Number of measures	Description
		Study 3 6-Week repeated Dosing Study of RVT-801 in Juvenile Farber Mice (RVT-801-9019).
Clinical studies	2	**Study 4** Randomized, double-blind placebo-controlled first-in-human dose escalation study of the safety and efficacy of intravenous RVT-801 in paediatric (and adult patients) with acid ceramidase deficiency presenting as Farber disease (RVT-801-3001). **Study 5** Open-label single arm extension safety and efficacy study in paediatric (and adult patients) with Farber disease completing Study 4 (RVT-801-3001); (RVT-801-3002).
Extrapolation, modelling and simulation studies	1	**Study 6** Modelling and simulation study, to evaluate the use of the RVT-801 in Farber disease in paediatric patients from 3 months to less than 18 years of age (and adult patients) (RVT-801-3001-3002).
Other studies	1	**Study 7** Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease (RVT-801-001).
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By April 2021
Deferral for one or more measures contained in the paediatric investigation plan:	No